AB Science will host a live webcast on Tuesday January 28, 2025, from 5.30pm to 6.45pm CET
PRESS RELEASE
Read more here:
AB Science will host a live webcast on Tuesday January 28, 2025, from 5.30pm to 6.45pm CET
Author Archives: admin
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
Daix (France), New York City (New York, United States), January 24, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) and other diseases with significant unmet medical needs, today announced the half-year report of its liquidity contract with Kepler Cheuvreux.
More here:
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DURHAM, N.C., Jan. 24, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on January 17, 2025, the Compensation Committee of Chimerix’s Board of Directors granted inducement awards to six new employees of non-statutory stock options to purchase up to a total of 355,000 shares of Chimerix’s common stock. The Compensation Committee of Chimerix’s Board of Directors approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing rule 5635(c)(4).
Read more here:
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated…
Investor webcast on Monday, January 27, 2025, at 8:00 a.m. ET to present clinical data
Go here to read the rest:
Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated...
Tevogen Bio Broadens Relationship with Microsoft to Deepen Artificial Intelligence Collaboration and Develop PredicTcell Technology on Azure
WARREN, N.J., Jan. 24, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen Bio” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T-cell therapeutics for infectious diseases and cancers, announced today that it has broadened its relationship with Microsoft (Nasdaq: MSFT) to broaden its AI-focused collaboration and build its PredicTcell technology. PredicTcell is Tevogen Bio’s proprietary technology designed for predictive precision T cell targeting. This expanded relationship is designed to harness Microsoft’s cutting-edge AI, cloud capabilities, and Microsoft’s health and life sciences domain expertise to accelerate Tevogen Bio’s target identification and pre-clinical processes, strengthening the company’s pipeline of innovative immunotherapies.
See the original post:
Tevogen Bio Broadens Relationship with Microsoft to Deepen Artificial Intelligence Collaboration and Develop PredicTcell Technology on Azure
FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment
Originally posted here:
FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
Roche announces new results from EMBARK demonstrating significant sustained benefits of Elevidys in ambulatory individuals with Duchenne muscular…
Basel, 27 January 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive topline results from year two of the EMBARK trial, a global, randomised, double-blind phase III study of Elevidys™ (delandistrogene moxeparvovec), the first approved gene therapy for the treatment of individuals with Duchenne muscular dystrophy. Two years after treatment with Elevidys, statistically significant and clinically meaningful improvements were observed across three key motor function measures of NSAA, TTR and 10MWR, when compared to a pre-specified propensity-weighted untreated external control group.* Functional differences between individuals treated with Elevidys and those in the external control group increased between one and two years after dosing. Together, these results demonstrate consistent, sustained benefit in favour of Elevidys.
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
COPENHAGEN, Denmark, January 27, 2025 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on January 9, 2025, under which the Company will repurchase shares for an amount up to DKK 150 million in the period from January 9, 2025 to February 5, 2025. The program is executed in accordance with Regulation (EU) No. 596/2014 (as amended) of the European Parliament and of the Council on market abuse and Commission Delegated Regulation (EU) 2016/1052, which together constitute the Safe Harbour Regulation.
Here is the original post:
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
Harness Therapeutics appoints Dr Heather Preston as Chair and secures new funding from Ono Venture Investment to accelerate delivery of…
Cambridge, UK, 27 January 2025: Harness Therapeutics (‘Harness’), a biotechnology company unlocking previously undruggable targets to transform the treatment of neurodegenerative diseases, today announces it has appointed Dr Heather Preston as new Non-Executive Chair, and has secured further funding to progress its lead programme in Huntington’s Disease. This brings on board pharmaceutical investor Ono Ventures Investment, joined by existing investors, Takeda Ventures, SV Health Investors’ Dementia Discovery Fund and Epidarex Capital.
See the original post here:
Harness Therapeutics appoints Dr Heather Preston as Chair and secures new funding from Ono Venture Investment to accelerate delivery of...
AB2 Bio signs U.S. option and licensing agreement with Nippon Shinyaku for Tadekinig alfa for an ultra-rare autoimmune disease
Lausanne (Switzerland), January 27, 2025 — AB2 Bio Ltd., a biotechnology company developing innovative therapies for the treatment of severe systemic hyperinflammatory diseases and conditions driven by IL-18, announced today it has entered into an option and licensing agreement with Nippon Shinyaku Co. Ltd., a leading Japanese pharmaceutical company with extensive experience in marketing rare disease therapeutics in the U.S.